Jeff Yass’s NovaBridge Biosciences American Depositary Shares NBP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-14,600
Closed -$55.2K 12933
2025
Q3
$55.2K Buy
+14,600
New +$49.6K ﹤0.01% 11830
2023
Q2
Sell
-18,400
Closed -$63.7K 12571
2023
Q1
$63.7K Buy
18,400
+6,800
+59% +$32.9K ﹤0.01% 11582
2022
Q4
$48.5K Buy
+11,600
New +$43.9K ﹤0.01% 11417
2022
Q2
Sell
-34,000
Closed -$552K 13372
2022
Q1
$552K Buy
34,000
+29,300
+623% +$751K ﹤0.01% 8725
2021
Q4
$223K Sell
4,700
-29,500
-86% -$1.77M ﹤0.01% 11213
2021
Q3
$2.48M Buy
34,200
+21,300
+165% +$1.54M ﹤0.01% 5372
2021
Q2
$1.08M Buy
12,900
+6,900
+115% +$455K ﹤0.01% 7547
2021
Q1
$291K Buy
+6,000
New +$326K ﹤0.01% 10668

Other funds holding NBP

Jeff Yass's NBP Position: Q2 2026 in Review

Jeff Yass increased its NovaBridge Biosciences American Depositary Shares (NBP) stake by 123% in Q2 2026, buying an estimated $32.1K and bringing the position to 28,539 shares worth $55.7K. The position accounts for ﹤0.01% of the portfolio, ranked #12791.

Jeff Yass first reported a position in NBP in Q2 2021 and has held it in 15 quarters since. The position peaked at $922K in Q2 2021. 49 funds tracked by Wall St. Rank hold NBP as of Q2 2026.

  • Jeff Yass held 28,539 shares of NovaBridge Biosciences American Depositary Shares worth $55.7K as of Q2 2026.
  • Jeff Yass bought 15,722 NovaBridge Biosciences American Depositary Shares shares in Q2 2026, an estimated $32.1K.
  • NovaBridge Biosciences American Depositary Shares made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #12791 holding.
  • Jeff Yass first reported a position in NovaBridge Biosciences American Depositary Shares in Q2 2021 and has held it in 15 quarters since.
  • Jeff Yass's NovaBridge Biosciences American Depositary Shares position peaked at $922K in Q2 2021.
  • 49 funds tracked by Wall St. Rank held NovaBridge Biosciences American Depositary Shares as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.